Heritage Pharmaceuticals, a generic pharmaceutical company headquartered in New Jersey, was charged with conspiring with competitors to fix prices, rig bids, and allocate customers, the Department of Justice announced Monday.
According to a one-count felony charge filed on May 30 in the U.S. District Court for the Eastern District of Pennsylvania, from about April 2014 until at least December 2015, Heritage participated in a criminal antitrust conspiracy with other companies and individuals engaged in the production and sale of generic pharmaceuticals, a purpose of which was to fix prices, rig bids, and allocate customers for glyburide, a medicine used to treat diabetes. This charge is the third in the Department of Justice’s Antitrust Division’s ongoing investigation; Heritage’s former CEO and its former president were previously charged.
